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Abstract 
Vagal Nerve Stimulation (VNS) has been a treatment of choice for pediatric patients with 
medically refractory epilepsy for over 20 years since FDA approval in 1997. It is relatively 
minimally-invasive to other surgical interventions, has few complications, and has a significant 
impact on decreasing the frequency, severity, and duration of seizures. This project sought to 
answer three main questions. What are the epidemiologic factors that are significant for 
pediatric medically refractory epilepsy? What are the best outcome predictors for VNS 
implantation? And finally, is there a way to improve rural physicians’ decision making abilities 
when referring patients for evaluation of VNS implantation?  
We evaluated a single-institution’s outcomes with VNS implantation and analyzed national data 
through the KID database with regards to cost disparities between rural and urban areas. At 
Phoenix Children’s Hospital, we found that of the 41 patients who had VNS implantation and 
met inclusion over a 6 year period, over 70% of patients achieved greater than 50% seizure 
frequency reduction. Other predictors of improved outcomes are device output current 
settings, as well as race. Of the national database, we have found that a disparity does exists, 
with rural patients on average waiting one year longer than urban patients to get the 
implantation. Other differences were found, such as length of stay. Rural patients had more 
neurologic comorbidities, and stayed on average 2 days less than urban patients. An 
educational webinar presentation was created, aimed at informing primary care physicians 
about the indications for VNS implantation. Ultimately we predict that with the webinar, more 
patients with intractable epilepsy will be evaluated earlier and eventually have implantation of 
the VNS device. Future work will use the webinar presentation to reduce the rural and non-
rural healthcare practice disparities that exist. 
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Introduction 
Epilepsy is a common pediatric problem, affecting 1% of the population with approximately 30% 
of children with epilepsy refractory to standard anticonvulsant medications1.  When appropriate, 
surgery offers these children a chance for seizure freedom and medication withdrawal, or seizure 
frequency and intensity reduction with medication reduction, along with an improved quality of 
life.  Over the last 15 years, the field has advanced technologically, made epilepsy surgery more 
readily available, and expanded the patient population that might potentially benefit.  Numerous 
surgical options are available to patients for cure including focal resection, lesionectomy, and 
hemispherectomy.  When cure is not possible, neuromodulation using vagus nerve stimulation 
(VNS) has been available for over 20 years2.  It is necessary to review our results from these 
epilepsy surgeries for continued growth in our understanding of the disease and further 
improvements in recommending therapeutic interventions. It is also important to share our 
results with the larger medical community to reinforce this option as a successful treatment for 
medically refractory epilepsy.  Without surgery as an option, most of these children will continue 
to have frequent seizures which will impact their quality of life and options for the future. 
Epilepsy surgery is felt by many in the medical community to be a last resort option and only used 
when every other treatment option has failed.  We have learned in the last 10 years that surgery 
is safe and effective and should be offered sooner.  Children who have surgery earlier recover 
more quickly and have improved development and cognitive function.  We have also learned that 
patients who fail to achieve seizure control on the first two anticonvulsant medications 
prescribed have less than a 10% chance of achieving seizure freedom with the next medication.  
Surgery offers a 50 – 80% chance of seizure freedom, depending on the procedure, with low 
complication rates.  One way to improve care for children with epilepsy is to review our data and 
share with the medical community to educate that surgery is a safe and effective option that 
should be offered sooner in the child’s treatment algorithm.  
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There has not been a considerable amount of research done regarding perioperative care for 
pediatric patients with drug-resistant epilepsy (medically refractory seizures). There also is no 
standard of care when it comes to follow up for these patients post-op. Finally, there needs to 
be an acceptable manner in which a complete standard of care is available and disseminated to 
patients in a rural setting. It is necessary to understand all of the possible complications post-
operatively, as well as the necessity to evaluate specific ways in which the seizures/epilepsy is 
being affected by the VNS (how the severity/frequency/hospital visits changes with respect to 
pre and post VNS implant, as well as adjustments that are made to the stimulating device). 
Surgical complications regarding VNS implantation are common, and should be further 
understood to increase the education of both physicians and patients. Vocal stridor, for example, 
is known to vary based on the coil diameter, and it is also understood that adjustments need to 
be made on an individual basis18. Also, while current studies show that VNS implantation does 
not reduce risk of premature death from Sudden Unexpected Death due to Epilepsy (SUDEP) as 
a result of the intractable epilepsy overall, improved outcomes with new technology such as with 
newer models of generators and closed loop systems, may have a different impact19. 
Besides improvements in our understanding of intractable epilepsy and its treatment, we need 
to consider the unique issues affecting rural populations. Strides have already been made to 
evaluate telehealth as an acceptable alternative to track epileptic patients, and thus we can try 
to see a large need to generate a standard protocol for evaluating rural pediatric VNS patients 
through a telehealth network3. Access to medical care in rural Arizona is an issue that affects 
pediatric epileptic patients. Rural isolation has been linked to a reason for the above average 
healthcare disparities observed for epileptic patients. Arizona falls below the USA average 
number of neurologists per 1000 patients with epilepsy (USA avg: 6.1, AZ avg: 5.8)4. With over 
12% of the AZ population living in rural residence, a tele-presence alternative should be sought 
for rural VNS patients. Additionally, there is not a solid literature base that describes the 
epidemiology of intractable epilepsy or pediatric patients’ responses to VNS implantation, and 
some foundational work to understand the population dynamics will be helpful in determining 
prospective patients to focus enrollment on. Cost utility studies have been done in developing 
countries such as Jordan, and researchers have concluded that VNS implantation was favorable 
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and lead to improvement in quality of life20. This notion should be applied to rural areas within 
Arizona, and thus can have similar expectations. 
In order to address the healthcare disparities within rural areas, continuing medical education 
programs have been developed which can be accessed online. Webinar style programs have been 
identified as having a significant influence on how surgeons and radiologists behave after 
participation in the program5. These webinars approach the large issue of reaching many 
individuals where access to such education is difficult due to location/distance. Projects such as 
this current one will address previously described needs to enhance community awareness 
within rural Arizona16. 
With regards to the VNS implants themselves, a majority of the physician and patient education 
is done through the producer of the implant7. Currently, physicians have to request education 
material, and if they are unaware of any developments or changes, there is the possibility that 
they will stay uninformed. Providing this information to rural physicians through a webinar has 
the possibility to increase awareness of up to date technology and indications for referring 
patients for evaluation for epilepsy surgery and the potential benefit of the VNS. 
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Materials and Methods 
Phase I: Retrospective 
Inclusion criteria were as follows: subjects were pediatric patients (all children ages birth to 21 
years) who had undergone VNS implantation surgery at Phoenix Children’s Hospital for the 
treatment of intractable epilepsy, between January 1, 2009 and November 30, 2015 and had 
follow-up at least for 6 months with documented device adjustments. Patients were excluded on 
the following basis: if their surgery was a re-implantation of a VNS or revision surgery, if there 
was not a complete clinical record, if they did not follow up for the minimum of 6 months, or if 
they had any other epilepsy surgeries performed after the VNS implantation. Rural patients were 
further identified by sorting the subject database by zip code and excluding all zip codes within 
the Phoenix and Tucson metropolitan areas. Table 1 lists inclusion and exclusion criteria. 
Data analyzed included where the subjects were referred from, pre-surgical work-up, surgical 
procedures performed, and outcomes including number of post-surgical seizures, 
neuropsychological results, and complications. Subject data was also looked at to analyze if 
anyone was lost to follow-up. The post-operative follow-up appointments were examined to 
determine what aspects of this care can be delivered through a telehealth model, in order to 
reduce potential “lost to follow-up” patients. 
A secondary database was examined to identify patients using the same subject criteria above, 
but applied to the entire country. We examined the following data elements of the KID national 
database in the years 2003, 2006, and 2009 to further understand the disparities between rural 
and urban patients: Age, gender, race, primary payer, hospital metrics, and patient location, 
length of stay, total charges, and presence of neurologic comorbidities.   
Phase I data retrieval through Phoenix Children’s Hospital as well as the national KID database, 
was accomplished with patient selection using CPT codes 64568 (Insertion of new cranial nerve 
stimulator and electrodes), Procedure Codes: 04.92, and 86.94, ICD 9 Codes: 345.01, 345.11, 
345.41, 345.51, 345.61, 345.71, 345.81, and 345.91, and ICD 10 codes: G40.019, G40.119, 
G40.219, G40.319, G40.419, G40.804, G40.919, and G40.B19. These numbers were retrieved 
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from cms.gov/medicare-coverage-database, and listed codes that contained the keywords 
"epilepsy, intractable, not status epilepticus". 
In order to adequately and effectively evaluate the outcomes for the subjects, we created a 
modified Engel Outcome Scale (mEOS). This scale aimed to take into account subjective and 
objective reporting, and was reported on a scale from 1-12. Table 2 outlines the data elements 
that go into calculating the mEOS. 
Phase II: Prospective 
Information about the retrospective study provided a basis for generating a webinar based 
educational tool for physicians and potential patients. The webinar incorporated best practices, 
best outcome predictors from the retrospective phase, as well as the well accepted literature 
regarding VNS implantation, and present the information in a narrative PowerPoint presentation 
with audio recording. Figure 1 demonstrates one example slide of the PowerPoint presentation. 
The entire presentation can be found in the supplemental figures section. 
Data Analysis 
For outcomes including changes in seizure frequency and duration and the EOS, we used the 
point bi-serial correlation and spearman correlation depending on the characteristics of 
variables. For example the values with seizure frequency change is considered an ordinal 
variable.  Any ordinal variables was correlated using spearman.  Any binary or nominal data was 
correlated using the point bi-serial. The outcomes defined by mEOS were more continuous thus 
we used simple linear regression to ascertain trends.    
Regarding the KID database data, a linear regression was performed to compare continuous 
variables. Fisher’s Exact Test was used to compare categorical variables. 
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Table 1. Inclusion and exclusion criteria for patient selection for retrospective analysis. 
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Table 2. Modified Engel Outcome Scale (mEOS). The mEOS is calculated using qualitative and 
quantitative data, including the Engel Outcome Scale (EOS), as well as changes in seizure 
frequency and duration. Adding up each column from 0-4 will yield a mEOS score ranging from 
0-12. 
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Figure 1. PowerPoint presentation example. 
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Results 
Outcomes from Phoenix Children’s Hospital (PCH) Data  
To elucidate the effects of VNS surgery, we sought to examine the outcomes at Phoenix 
Children’s Hospital. Eighty-one patients were initially identified having met inclusion criteria, and 
forty were excluded based on the exclusion criteria. Of the reasons patients were excluded, most 
common was not enough records or no follow-up documentation beyond 6 months (23 patients), 
incorrect timing of VNS placement (16 patients), or concurrent epilepsy surgery (1 patient with 
corpus callosotomy performed within the same hospitalization as VNS implantation). Patients 
were relatively evenly split between male and female, with 18 male and 23 female patients. The 
most predominant race was White (31 patients), followed by Hispanic (7 patients), Native 
American (2 patients), and Black (1 patient).  
The average age at seizure onset was 4.1 years (standard deviation ±4.8 years), and the average 
age at implantation was 10.02 years (standard deviation ±5.7 years), with a total average time of 
5.92 years from diagnosis until implantation. Twenty-five patients had some form of congenital 
neurodevelopmental delay, the most common being autism (7 patients) and cerebral palsy (5 
patients), followed by rare congenital disorders such as Aicardi Syndrome, Tuberous sclerosis, 
and Lennox-Gastaut Syndrome.  Seizure types were broken down into 3 categories: non-focal, 
focal, and both. In total, 31 patients experienced only non-focal seizure types, 5 patients 
experienced only focal seizures, and 5 with both. Only one patient had their seizure type change 
after VNS implantation, when a patient started out with only focal seizures, and then went on to 
develop non-focal seizures after implantation.  
On average, patients were tried on 5.1 (standard deviation ±1.9 AEDs) anti-epileptic drugs (AEDs), 
with 5 being the most common. After VNS implantation, the average AED use dropped down to 
3.0 (standard deviation ±1.5 AEDs), with 3 being the most common (p < 0.05). Complications 
included cough (2.4%), device infection (4.9%), and changes to voice (7.3%). The average length 
of follow-up was 3.7 years (standard deviation ±1.7 years), and the average number of follow-up 
visits documented in that time was 13.5 (standard deviation ±9.5 visits). The average Engel 
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Outcome Score was 2.8 (standard deviation ±1.15). The average modified Engel Outcome Score 
(mEOS) was 7.15 (standard deviation ±3.49). With regards to change in seizure frequency, 39 
patients had documented changes. Greater than 90% seizure frequency reduction was achieved 
in 17 (43.6%) patients, 12 (30.8%) patients achieved greater than 50% seizure frequency 
reduction, 3 (7.7%) patients achieved greater than 10% decrease, and 7 (17.9%) experienced no 
appreciable change in seizure frequency. Seizure duration change was only documented in 29 
patients. Six patients (20.7%) achieved greater than 90% reduction in seizure duration, 8 (27.6%) 
patients achieved greater than 50% reduction in seizure duration, 3 (10.3%) patients achieved 
greater than 10% reduction in seizure duration, 10 (34.5%) patients achieved no change in seizure 
duration, and 2 (6.9%) patients had an increase in the duration of their seizures.  
Predictors of Improved Outcomes 
Many variables were examined in this study, ranging from demographics, to seizure and epilepsy 
characteristics, to device settings. Female gender was associated with improved outcomes 
defined by the EOS (p < 0.05). Race had a near significant relationship with outcomes defined by 
the mEOS, with Whites having better outcomes than Hispanics, and Hispanics having better 
outcomes compared to Native Americans (p = 0.059). Device output current was associated with 
a decrease in the seizure frequency (p = 0.0008), with 1.75 mA being associated with the lowest 
mEOS score. An increase in the device pulse width was associated with improved mEOS scores (p 
= 0.011). Other settings such as on and off time, signal frequency, and magnet settings did not 
alter outcomes in any statistically significant manner.  
Disparities in Healthcare Delivery 
We first examined patient demographic data from the PCH database. We were only able to find 
two patients out of forty-one that lived outside of urban zip-codes. Figure 2 shows a map of 
Arizona and includes where the patients’ zip codes are.  
Next, we examined the KID national database over the years 2003, 2006, and 2009, and extracted 
patient data from 1,015 patients with similar selection criteria as explained in the methods 
section above. The distribution of patients across the 3 years was relatively equal, each between 
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30-35% of the 1,015 patients. Gender was roughly split evenly, with 50.1% of the sample being 
female. Age at time of procedure was 10.2 years on average. Patients were majority Caucasian, 
approximately 70%, followed by 15.9% Hispanic, and 6.4% African American. Primary payer for 
the majority of patients was private insurance, at 54.3%, followed by Medicaid 40.6%. Most 
hospitals that performed the VNS implantation had urban designation; 98.6% of procedures done 
were done in urban hospitals, and 1.4% done at rural centers. Most patients lived in areas with 
population greater than 50,000 people, with only 9.7% of patients living in areas that had less 
than 50,000 people. 
After comparing the rural and urban hospitals, we obtained the following data. Between the 
1,015 patients over the 3 years, only 26 patients had their VNS implantation done at rural 
hospitals. The age of patients who had received VNS implantation at rural centers compared to 
urban was on average 1.1 years older, 11.4 compared to 10.3 years at rural and urban hospitals, 
respectively (p = 0.003).  Medicaid was the majority primary payer for the rural patients, at 
approximately 71.9%, compared to only being primary payer for 39.1% of patients at urban 
hospitals (p = 0.10). Length of stay were lower in the rural hospitals, with patients staying a total 
of 1.36 days compared to urban hospitals of 3.82 days (p < 0.001). Total charges had a similar 
relationship, with rural hospitals charging $31,886.50 compared to $47,592.80 at urban hospitals 
(p < 0.001).  
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Table 3. Phoenix Children’s Hospital Patient Characteristics.  
Eighty-one patients met the inclusion criteria, and 40 patients were excluded. 
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Table 4. Phoenix Children’s Hospital Patient Data. 
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Figure 2. Map of Arizona including patient distribution. Patient “pins” on the map are 
determined by zip-code. Two out of forty-one zip codes were classified as rural. 
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Table 5. Characteristics of patient data from KID Database. Patient data obtained over multiple 
years (2003, 2006, 2009). Demographically, patients are majority Caucasian, and live in 
populations over 50,000 people.  
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Table 6. Comparison of variables between rural and urban patients. On average, patients with 
VNS implantation at rural hospitals were 1.1 years older than patients at urban hospitals. Patients 
at rural hospitals had shorter length of stays and decreased total charges compared to urban 
hospital patients. 
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Discussion 
After performing a retrospective single-institution validation review of the efficacy of vagal nerve 
stimulation for pediatric medically refractory epilepsy, we have confirmed that this is a safe, 
minimally invasive, and effective method to reduce the seizure burden. Race seemed to play a 
role in the outcomes, with White patients having lower modified Engel Outcome Scores 
compared to Hispanics, and Hispanics having lower modified Engel Outcome Scores when 
compared to Native Americans. While this arm of the study did not look into the socioeconomic 
status with relation to these patients, it could play a role into the reasoning for the difference in 
outcomes. Genetics may also play a role in the race disparity.  
Vagal nerve stimulation in general is indicated in generalized and non-focal epilepsy, and 30/41 
patients had only non-focal seizure types, with 5 patients who had only focal seizures, and 5 
patients who had both focal and non-focal seizures. This is a self-selecting group, as most patients 
being referred for implantation were from non-rural areas, and referred by specialists such as 
child neurologists. We anticipate that one of the reasons for a decrease in the rural referral base 
is due to the lack of knowledge regarding the indications for referral.  
The safety of the surgery is also well documented, prior to this study. Our data conclude that the 
complications associated with implantation were rare, and only included minor complications 
such as temporary cough, or surgical site infections. Many of these complications were transient, 
and physicians were able to mitigate symptoms by reducing the amplitude of stimulation from 
the device. The device implantation also did not alter the pathology of the seizures in harmful 
ways, with only one patient developing a new seizure type after the surgery. 
We created a useful tool in the evaluation of seizure activity before and after epilepsy surgery. 
The Engel Outcome Scale (EOS) has been widely used, however it is largely subjective and has the 
potential of creating low inter-rater reliability. The modified Engel Outcome scale (mEOS) that 
was utilized for this study incorporate both the subjective nature of the original EOS, as well as 
more objective measures such as changes in seizure frequency and duration. We anticipate 
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scoring methods such as the mEOS can be used to obtain a more holistic understanding of the 
impact epilepsy surgery has on patients. 
Follow up after VNS implantation is critical, as the device is not immediately therapeutic in the 
post-operative period. Multiple follow-up appointments are required to increase the dose of 
stimulation current, as well as other settings that need to be fine-tuned to suit the needs of the 
patient. We found that the most common device setting associated with improved outcomes was 
a device output current of 1.75 mA, which can be used to inform future providers when making 
adjustments to the VNS. While our study did not conclude what the effects of other settings are, 
such as pulse width, on and off time, signal frequency, and magnet settings, it is important to 
further examine the relationship between these settings in a higher power study. Having a 
greater understanding of the electrophysiologic interplay between the stimulator settings and 
the effects on seizure activity can assist with troubleshooting as well as potentially reducing the 
amount of follow-up appointments. Further study into the electrophysiology is required to 
understand the mechanisms of specific device settings with regards to epilepsy. 
When assessing the disparities between rural and urban patients, the Phoenix Children’s Hospital 
data was deemed to be insufficient, as only 2 patients were located in “rural” zip-codes, as 
defined by the Centers for Medicare and Medicaid Services21.  
It is useful to take a small tangent and discuss the difficulty with studying disparities between 
rural and non-rural patients. There is currently no agreed-upon definition for any location to get 
the “rural” designation. For the purposes of this paper, we have chosen to cite the United States 
Census Bureau, which defines an urbanized areas as 50,000 or more people, and “whatever is 
not urban is considered rural.”22 When applicable, zip-codes have rural and urban designations 
as defined by CMS, which was also a definition that was taken into consideration for this paper. 
A healthcare disparity exists between rural and urban pediatric patients who are suffering from 
medically refractory epilepsy. The first disparity is a simple comparison between the ratios of 
patients in our sample who are rural and of all rural persons in the United States. Only roughly 
9% of patients in the data can be categorized as living in rural locations, compared to the 19.3% 
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of persons in the United States who live in rural areas23. Given no epidemiologic studies that 
show any differences in the rate of medically refractory epilepsy with relation to geographic 
location, the rates of rural patients who receive VNS implantation should be close to 19.3%. 
Possible explanations for this could be that patients are simply not being referred enough for 
escalation of therapy by their rural primary care pediatricians. Other contributing factors also 
come from the difficulties associated with traveling to tertiary care centers, which can potentially 
be hours away from the patients’ homes.  
A second glaring disparity exists between these patients. On average, patients who received the 
VNS implantation at rural centers were over 1 year older than patients at urban hospitals. While, 
older age at VNS implantation does not portend worse outcomes, it can be inferred that rural 
patients on average had to deal with the consequences of medically refractory epilepsy longer 
than urban patients24. Such consequences for example can be suffering from debilitating 
seizures.  
One last and surprising disparity was found between rural and urban hospitals. Patients at rural 
hospitals stayed on average 2 days less than patients at urban hospitals. This seems to be a 
standard and well reported finding, with all rural hospitals having length of stays on average 
about 2 days less than urban hospitals25. It must be mentioned that VNS implantation is done as 
an outpatient surgery, with most patients at large epilepsy centers going home within the same 
day as their implantation. We must then infer that patients that have protracted hospital stays 
longer than one day are due to patients who are already in the hospital for evaluation and then 
go straight to VNS implantation as an inpatient. Finally, we must further examine the data as to 
why rural hospitals are performing VNS implantation in the first place, where it is usually done in 
larger urban epilepsy centers. 
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Future Directions 
This project has established the well-known efficacy of vagal nerve stimulation for use in pediatric 
patients with medically refractory epilepsy. With the creation of the modified Engel Outcome 
Scale, we anticipate wider use of this scoring system, as it incorporates both qualitative and 
quantitative information. Lastly, we hope to further the study of the telemedicine presentations 
as a model to disseminate information and reduce healthcare disparities in rural areas.  
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Conclusions 
This study aimed to answer 3 main questions regarding vagal nerve stimulation for use in 
pediatric patients with medically refractory epilepsy. We performed a retrospective single 
institution validation study to confirm the efficacy of pediatric VNS, and found that at Phoenix 
Children’s Hospital, the majority of patients experienced significant and worthwhile reduction in 
seizure quality, duration, and frequency. We found variables that are associated with improved 
outcomes, including race, as well as device settings. Lastly, we found a disparity that exists 
between rural and non-rural patients in regards to VNS implantation. Such disparities include 
rural patients likely not being referred for VNS evaluation, as well as waiting longer to get the 
procedure done. We developed steps to address this disparity through a prototype telemedicine 
educational presentation aimed at informing rural primary care physicians about the indications 
for VNS referral. Our study paves the way for further understanding of the predictors for 
improved outcomes after VNS implantation, along with attempts at reducing healthcare 
disparities in rural areas. 
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